Tekla Capital Management’s AC Immune ACIU Stock Holding History

Tekla Capital Management’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-171,813	Closed	-$888K	–	197
2020 Q4	$888K	Hold	171,813	–	–	0.03%	181
2020 Q3	$838K	Hold	171,813	–	–	0.03%	184
2020 Q2	$1.16M	Hold	171,813	–	–	0.04%	190
2020 Q1	$1.19M	Hold	171,813	–	–	0.05%	166
2019 Q4	$1.46M	Hold	171,813	–	–	0.06%	165
2019 Q3	$850K	Hold	171,813	–	–	0.04%	165
2019 Q2	$954K	Hold	171,813	–	–	0.04%	165
2019 Q1	$868K	Hold	171,813	–	–	0.04%	166
2018 Q4	$1.62M	Hold	171,813	–	–	0.07%	141
2018 Q3	$1.38M	Hold	171,813	–	–	0.05%	173
2018 Q2	$1.6M	Hold	171,813	–	–	0.06%	144
2018 Q1	$1.78M	Hold	171,813	–	–	0.07%	143
2017 Q4	$2.2M	Buy	171,813 +130,894	+320%	+$1.54M	0.08%	123
2017 Q3	$462K	Buy	+40,919	New	+$350K	0.02%	145

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

Tekla Capital Management's ACIU Position: Q1 2021 in Review

Tekla Capital Management sold out of AC Immune (ACIU) in Q1 2021, closing a stake of 171,813 shares — an estimated $888K sold.

Tekla Capital Management first reported a position in ACIU in Q3 2017 and held it in 14 quarters. The position peaked at $2.2M in Q4 2017. 51 funds tracked by Wall St. Rank hold ACIU as of Q1 2021.

Tekla Capital Management reported no remaining AC Immune position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 171,813 AC Immune shares in Q1 2021, an estimated $888K.
Tekla Capital Management first reported a position in AC Immune in Q3 2017 and held it in 14 quarters.
Tekla Capital Management's AC Immune position peaked at $2.2M in Q4 2017.
51 funds tracked by Wall St. Rank held AC Immune as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.